Avalon GloboCare (NASDAQ:ALBT) Posts Quarterly Earnings Results

by · The Cerbat Gem

Avalon GloboCare (NASDAQ:ALBT – Get Free Report) issued its quarterly earnings data on Monday. The company reported ($0.49) earnings per share (EPS) for the quarter, Zacks reports.

Avalon GloboCare Stock Performance

Shares of Avalon GloboCare stock remained flat at $0.40 during midday trading on Monday. The company had a trading volume of 423,324 shares, compared to its average volume of 5,157,586. The stock’s fifty day moving average is $0.60 and its two-hundred day moving average is $1.07. The stock has a market capitalization of $3.33 million, a price-to-earnings ratio of -0.11 and a beta of -0.04. Avalon GloboCare has a one year low of $0.34 and a one year high of $4.74.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Avalon GloboCare in a research report on Monday, April 20th. One analyst has rated the stock with a Sell rating, According to MarketBeat, Avalon GloboCare currently has a consensus rating of “Sell”.

Check Out Our Latest Research Report on ALBT

About Avalon GloboCare

(Get Free Report)

Avalon GloboCare is a clinical-stage biopharmaceutical company specializing in the research, development and commercialization of next-generation cell-based therapies and exosome-based diagnostics. The company’s pipeline focuses on allogeneic chimeric antigen receptor T-cell (CAR-T) and CAR-natural killer (CAR-NK) programs targeting hematological malignancies and solid tumors, alongside proprietary exosome platforms for noninvasive cancer detection.

Through its R&D facilities in both the United States and China, Avalon GloboCare integrates cell engineering, genetic modification and biomarker discovery to advance therapeutic and diagnostic candidates from preclinical research into human studies.

Read More